MLP3 LLC’s AbbVie ABBV Stock Holding History

MLP3 LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$563K	Buy	2,590 +4	+0.2%	+$887	0.62%	37
2025 Q4	$591K	Buy	+2,586	New	+$589K	0.65%	36

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MLP3 LLC's ABBV Position: Q1 2026 in Review

MLP3 LLC increased its AbbVie (ABBV) stake by 0.15% in Q1 2026, buying an estimated $887 and bringing the position to 2,590 shares worth $563K. The position accounts for 0.62% of the portfolio, ranked #37.

MLP3 LLC first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. The position peaked at $591K in Q4 2025. 4,102 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

MLP3 LLC held 2,590 shares of AbbVie worth $563K as of Q1 2026.
MLP3 LLC bought 4 AbbVie shares in Q1 2026, an estimated $887.
AbbVie made up 0.62% of MLP3 LLC's portfolio in Q1 2026, its #37 holding.
MLP3 LLC first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
MLP3 LLC's AbbVie position peaked at $591K in Q4 2025.
4,102 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on MLP3 LLC's 13F filing for Q1 2026, filed 13 Apr 2026.